GLP1R and type 2 diabetes mellitus: An additional recent phase II randomized, double-blind, parallel-group, placebo-controlled study assessed the effects on HbA1c and body weight of multiple rising doses of survodutide, another dual GLP-1/GCG RA, compared to placebo and semaglutide in T2DM patients [112].